MelanomaNRAS Clinical Trials
NRAS mutations occur in approximately 15–20% of cutaneous melanoma and define a subgroup with aggressive biology, poor response to BRAF inhibitors, and historically limited targeted options. MEK inhibitor monotherapy (binimetinib) has demonstrated modest activity in NRAS-mutant melanoma. Trials explore MEK inhibitor combinations with CDK4/6 inhibitors (to block MEK-resistance bypass through cyclin D1), immunotherapy combinations, and novel RAS-directed approaches.
Top recruiting NRAS Melanoma trials
Ranked by phase and US site count. See all 6 trials matched to your profile →
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
Shanghai Kechow Pharma, Inc.
Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma
Hanmi Pharmaceutical Company Limited
Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial
Fudan University
Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations
N.N. Petrov National Medical Research Center of Oncology
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
Nested Therapeutics, Inc
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
UNC Lineberger Comprehensive Cancer Center
Browse other molecular targets with active Melanoma trials.